Jane Street Group LLC Sells 119,531 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Jane Street Group LLC trimmed its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 65.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,415 shares of the biotechnology company's stock after selling 119,531 shares during the period. Jane Street Group LLC owned about 0.07% of Anavex Life Sciences worth $355,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Nwam LLC bought a new position in Anavex Life Sciences during the third quarter valued at about $5,172,000. Charles Schwab Investment Management Inc. lifted its holdings in Anavex Life Sciences by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company's stock worth $3,783,000 after purchasing an additional 14,892 shares during the last quarter. Renaissance Technologies LLC boosted its position in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company's stock worth $1,968,000 after purchasing an additional 386,537 shares during the period. Bank of New York Mellon Corp grew its holdings in Anavex Life Sciences by 17.1% during the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company's stock valued at $1,184,000 after purchasing an additional 40,895 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Anavex Life Sciences by 15.8% in the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company's stock valued at $503,000 after purchasing an additional 16,293 shares during the period. Institutional investors and hedge funds own 31.55% of the company's stock.

Analysts Set New Price Targets

AVXL has been the topic of a number of research analyst reports. D. Boral Capital reiterated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday, December 23rd. HC Wainwright raised their price target on Anavex Life Sciences from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, December 26th.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock traded down $2.03 during midday trading on Thursday, hitting $11.43. The company had a trading volume of 3,356,612 shares, compared to its average volume of 2,788,386. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44. The business's 50 day simple moving average is $9.40 and its two-hundred day simple moving average is $6.92. The stock has a market cap of $969.45 million, a PE ratio of -22.86 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, sell-side analysts expect that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.